Menu Search
Equities

cbdMD Inc

YCBD:ASQ

cbdMD Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.4801
  • Today's Change-0.001 / -0.19%
  • Shares traded5.45k
  • 1 Year change-58.61%
  • Beta2.0164
Data delayed at least 15 minutes, as of Sep 20 2024 18:18 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year cbdMD Inc had revenues fall -31.77% from 35.40m to 24.16m, though the company grew net income from a loss of 70.08m to a smaller loss of 22.94m.
Gross margin63.43%
Net profit margin-94.12%
Operating margin-87.75%
Return on assets-82.98%
Return on equity-162.95%
Return on investment-112.36%
More ▼

Cash flow in USDView more

In 2023, cash reserves at cbdMD Inc fell by 4.92m. However, Cash Flow from Investing totalled 702.45k, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 4.30m for operations while cash used for financing totalled 1.32m.
Cash flow per share-8.32
Price/Cash flow per share--
Book value per share0.8055
Tangible book value per share0.0871
More ▼

Balance sheet in USDView more

cbdMD Inc has a Debt to Total Capital ratio of 31.28%, a higher figure than the previous year's 0.00%.
Current ratio0.9278
Quick ratio0.5172
Total debt/total equity0.4551
Total debt/total capital0.3128
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.